Trial Profile
The purpose of this study is to determine the safety and efficacy of AKR-501 (avatrombopag) administered in participants with chronic Idiopathic Thrombocytopenic Purpura (ITP) who were enrolled into and completed 28 days of study treatment in Protocol 501-CL-003 (NCT00441090).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2021
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Eisai Inc
- 08 Dec 2020 Results of a pooled analysis assessing the efficacy profile of AVA across its clinical development program (comprised of 4 phase 2 and 3 studies, CL-003,CL-004, study 302 and study 305), presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 13 May 2014 New trial record
- 06 May 2014 Results published in the Blood.